certificate of analysis is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-06-16. Numbers and descriptions here follow the published literature rather than marketing material.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small-molecule REV-ERB agonist | Not a hormone or natural product |
| Primary targets | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian and metabolic regulation |
| Appearance | White to off-white solid | Typical for purified research samples |
| Solubility | Soluble in DMSO and ethanol; low water solubility | Laboratory solubility depends on solvent and purity |
| Common synonyms | SR9009; Stenabolic | Stenabolic is a colloquial name, not a formal chemical name |
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
=== Nuclear === In addition to its reported mitochondrial function, some researchers have proposed a very small pool of active nuclear SIRT3 exists. This pool is reported to consist of the long form of SIRT3 and has been suggested to have histone deacetylase activity. The observation that SIRT3 has nuclear activity came from a report that SIRT3 protected cardiomyocytes from stress mediated cell death and that this effect was due to deacetylation of a nuclear factor, Ku-70.
== Continuous production == A common method of increasing efficiency in industrial chromatography is continuous production. There, this is done with SMB (Simulated Moving Bed). In liquid-liquid chromatography, there is no need to simulate a moving bed, as we can move it in reality, and therefore it is TMB, i.e. True Moving Bed. The essence of TMB is to continuously switch the device between ASC and DSC modes, effectively creating a moving bed. This technique is much cheaper than SMB, and its efficiency is not lagging behind. TMB systems are available from mg to tone capacity from LiLiChro.
=== South America === Argentina: President Javier Milei celebrated the capture of Maduro and his wife by posting on social media: "liberty advances, ¡Viva la libertad, carajo!". In an interview with local media, Milei said that Maduro "clung on to power" and ran a regime "rigging elections", reaffirming that his capture was "excellent news for the free world". On 7 January, Milei expressed support for the US taking control of the Venezuelan oil industry, arguing that it will "cut (the) supply of communists." Bolivia: The Ministry of Foreign Affairs expressed support for the Venezuelan people in their path to recover "democracy, constitutional order, and human rights", while reaffirming Bolivia's commitment to Venezuela's stability and humanitarian assistance. President Rodrigo Paz later stated that "freedom is not negotiable" and that "the way out for Venezuela is to respect the vote". On January 4 Bolivia imposed travel restrictions to members of the security forces of Venezuela as well as Venezuelan officials and former officials of the Maduro government. Brazil: President Luiz Inácio Lula da Silva condemned the strikes and the capture of Maduro, referring to them as a "very serious affront to the sovereignty of Venezuela and a extremely dangerous precedent to all the international community". On 4 January 2026, Brazil, Spain, Chile, Colombia, Mexico, and Uruguay issued a joint statement to express their "profound concern and firm rejection of the military actions carried out unilaterally in Venezuelan territory" by the United States.
== External links == Anatomy Atlases – Microscopic Anatomy, plate 09.175 - "Spleen: Red Pulp" Histology image: 07803loa – Histology Learning System at Boston University - "Lymphoid Tissues and Organs: splenic reticulum"
=== SARM1 === SARM1 is a Toll-like receptor protein and also functions as a intracellular NADase. Under normal circumstances NADase activity are inhibited in the presence of NAD+, where NAD+ binds to armadillo/heat motifs (ARMs), which inhibits the dimerization of the toll-like receptor domain that activates the NADase activity. If there are damages to the binding site of NAD+ or disruption that prevents the interaction between ARMs and the toll-like receptor domain, NADase activity will be turned on at a constitutive level. As a result SARM1 will have higher consumption of NAD+ and produce NADase products (ADP-ribose and nicotinamide) rather than the production of cADPR from ADP-ribosyl cyclase.
Sources: en.wikipedia.org
== Structure == SUMO proteins are small; most are around 100 amino acids in length and 12 kDa in mass. The exact length and mass varies between SUMO family members and depends on which organism the protein comes from. Although SUMO has very little sequence identity with ubiquitin (less than 20%) at the amino acid level, it has a nearly identical structural fold. SUMO protein has a unique N-terminal extension of 10-25 amino acids which other ubiquitin-like proteins do not have. This N-terminal is found related to the formation of SUMO chains. The structure of human SUMO1 is depicted on the right. It shows SUMO1 as a globular protein with both ends of the amino acid chain (shown in red and blue) sticking out of the protein's centre. The spherical core consists of an alpha helix and a beta sheet. The diagrams shown are based on an NMR analysis of the protein in solution.
=== brGDGT === The building blocks of brGDGT, specifically the long alkyl groups (iso-diabolic acid), are detected in acidobacteria subdivisions 1, 3, 4, and 6. Small amounts of brGDGT-I was detected in Acidobacteriaceae strain A2-4c by full mass spectrum and tentatively in Acidobacteriaceae strain 307 by single-ion monitoring MS; none has been detected in the 44 other strains tested as of 2018. More complex brGDGTs known from nature have not yet been detected in any cell culture.
In a 3 January 2026 editorial, The New York Times editorial board condemned the attack as "dangerous and illegal", describing it as an act of "latter-day imperialism" which lacked "any semblance of international legitimacy, valid legal authority or domestic endorsement". Comparing the attack to interventions in Libya, the war in Afghanistan, and US involvement in Nicaragua, it warned of the "potential for chaos in Venezuela", including violence from paramilitary groups such as the Venezuelan colectivos or the Colombian National Liberation Army (ELN), which operates in western Venezuela. The AFL-CIO condemned the attack, calling it unconstitutional. Many analysts liken the operation in Venezuela to prior operations, such as Operation Nifty Package which led to the capture of Panamanian military leader, Manuel Noriega, as well as Operation Red Dawn, which led to the capture of former Iraqi president, Saddam Hussein.
Tuftsin (L-threonyl-L-lysyl-L-prolyl-L-arginine) is a peptide related primarily to the immune system function. Rigin (glycyl-L-glutaminyl-L-prolyl-L-arginine) is a tetrapeptide with functions similar to those of tuftsin. Postin (Lys-Pro-Pro-Arg) is the N-terminal tetrapeptide of cystatin C and an antagonist of tuftsin. Endomorphin-1 (H-Tyr-Pro-Trp-Phe-NH2) and endomorphin-2 (H-Tyr-Pro-Phe-Phe-NH2) are peptide amides with the highest known affinity and specificity for the μ opioid receptor. Morphiceptin (H-Tyr-Pro-Phe-Pro-NH2) is a casomorphin peptide isolated from β-casein. Gluten exorphines A4 (H-Gly-Tyr-Tyr-Pro-OH) and B4 (H-Tyr-Gly-Gly-Trp-OH) are peptides isolated from gluten. Tyrosine-MIF-1 (H-Tyr-Pro-Leu-Gly-NH2) is an endogenous opioid modulator. Tetragastrin (N-((phenylmethoxy)carbonyl)-L-tryptophyl-L-methionyl-L-aspartyl-L-phenylalaninamide) is the C-terminal tetrapeptide of gastrin. It is the smallest peptide fragment of gastrin which has the same physiological and pharmacological activity as gastrin. Kentsin (H-Thr-Pro-Arg-Lys-OH) is a contraceptive peptide first isolated from female hamsters. Achatin-I (glycyl-phenylalanyl-alanyl-aspartic acid) is a neuroexcitatory tetrapeptide from giant African snail (Achatina fulica). Tentoxin (cyclo(N-methyl-L-alanyl-L-leucyl-N-methyl-trans-dehydrophenyl-alanyl-glycyl)) is a natural cyclic tetrapeptide produced by phytopathogenic fungi from genus Alternaria. Rapastinel (H-Thr-Pro-Pro-Thr-NH2) is a partial agonist of the NMDA receptor.
Daniel Siebert identified salvinorin A as the active constituent of Salvia divinorum via self-experimentation in 1993 and published these findings in 1994. Jonathan Ott published a paper on use of salvinorin A by various means and its effects in 1995. D. M. Turner published his book Salvinorin: The Psychedelic Essence of Salvia Divinorum, further describing salvinorin A's hallucinogenic effects in humans, in 1996. Salvinorin A was identified as a highly selective and potent κ-opioid receptor (KOR) agonist by Bryan L. Roth and colleagues in 2002. Dennis McKenna has shared that he identified salvinorin A as an extremely high-affinity KOR ligand while working at Shaman Pharmaceuticals in the early 1990s, but did not publish his findings as he could not believe how potent it was and thought that his results were erroneous. Roland Griffiths and colleagues and other researchers characterized the effects of salvinorin A in humans in formal clinical studies in the 2010s. Griffiths and colleagues further showed that salvinorin A's hallucinogenic and other effects in humans were blocked by the KOR antagonist naltrexone in 2016.
Sources: en.wikipedia.org
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.
It binds REV-ERBα and REV-ERBβ and changes transcription of metabolic genes. This can affect circadian rhythm, lipid use, and mitochondrial function. The full downstream effects are still under study.
No. Some rodent studies show increased endurance, but controlled human trials are lacking. Claims about human performance are not established by published evidence.
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.